Tripla negatív emlőrák: vizsgálatok itt: Ausztrália
31 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Blacktown, Frankston
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - 3. fázisTaking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Camperdown, Clayton, North Ryde, Westmead
- Életkor
- 18 év and over
- People
- 2400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - 1/2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Melbourne, Murdoch
- Életkor
- 18 év and over
- People
- 1132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Brisbane, Frankston, Macquarie University, Westmead
- Életkor
- 18 év and over
- People
- 1530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Where
- Adelaide, Bendigo, Cairns, Campbelltown, Clayton, Darlinghurst, Douglass, Gateshead, Murdoch, Port Macquarie, Woolloongabba
- Életkor
- 18 év and over
- People
- 1514 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00 - 1. fázisTaking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Adelaide, QLD
- Életkor
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Darlinghurst, Nedlands
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Korai 1. fázisTaking people177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- Where
- Adelaide, Gosford, Kingswood, Murdoch, Southport, Wollongong
- Életkor
- 18 év and over
- People
- 30
- Run by
- Radiopharm Theranostics, Ltd
See details and how to joinNCT06305962 - 3. fázisTaking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Adelaide, Darlinghurst, Frankston, Melbourne, Westmead
- Életkor
- 18 év and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - 1/2. fázisTaking peopleIntratumoral N17350 in Advanced Solid Tumors
- Where
- Melbourne, Newcastle, Westmead
- Életkor
- 18 év and over
- People
- 275 worldwide
- Run by
- Onchilles Pharma Inc
See details and how to joinNCT07339176 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Camperdown, Heidelberg
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Korai 1. fázisTaking peopleImaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
- Where
- Nedlands, Perth, St Leonards
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- RayzeBio, Inc.
See details and how to joinNCT07671092 - 1. fázisTaking peopleA Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
- Where
- Darlinghurst
- Életkor
- 18 év and over
- People
- 66 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07801508 - 1/2. fázisTaking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- East Melbourne
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - 1. fázisTaking peopleA Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
- Where
- Gold Coast, Heidelberg, Newcastle, Perth, Wahroonga, Westmead
- Életkor
- 18 év and over
- People
- 162
- Run by
- Context Therapeutics Inc.
See details and how to joinNCT07545122 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Bedford Park, Camperdown, Clayton, Nedlands, South Brisbane
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 1/2. fázisTaking peopleStudy of AVZO-021 in Patients With Advanced Solid Tumors
- Where
- Macquarie University, Wollongong
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Avenzo Therapeutics, Inc.
See details and how to joinNCT05867251 - 3. fázisTaking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- Camperdown, Darlinghurst, Heidelberg, Melbourne, Nedlands, Waratah
- Életkor
- 18 év and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - 1. fázisTaking peopleA Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Where
- Adelaide, Brisbane, Camperdown, Geelong, Sydney
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- Kivu Bioscience Inc.
See details and how to joinNCT07229313 - 1/2. fázisTaking peopleA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Where
- Liverpool, Melbourne, Subiaco, Woolloongabba
- Életkor
- 18 év and over
- People
- 416 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06618287 - 1. fázisTaking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Southport, Waratah
- Életkor
- 18 év to 75 év
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - 1/2. fázisTaking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Blacktown, Brisbane, Liverpool, Malvern, Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 1109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - 1. fázisNot yet taking people in AusztráliaA Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
- Where
- Nedlands
- Életkor
- 18 év and over
- People
- 16
- Run by
- Radiopharm Theranostics, Ltd
See details and how to joinNCT07272642 - 1/2. fázisTaking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Melbourne, Sydney
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - 2/3. fázisTaking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Ballarat Central, Brisbane, Heidelberg, Macquarie University, Melbourne, Subiaco
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00